Can You Take Vardenafil (Levitra/Staxyn) with Progesterone HRT?

Pharmacokinetic Overlap: CYP3A4 Metabolism

Both vardenafil and oral micronized progesterone are substrates of cytochrome P450 3A4 (CYP3A4), the enzyme responsible for approximately 60% of drug metabolism in the liver. Vardenafil's FDA label explicitly identifies CYP3A4 as its primary metabolic pathway, with CYP3A5 and CYP2C as minor contributors [1]. Oral micronized progesterone (Prometrium) undergoes extensive first-pass hepatic metabolism, primarily via CYP3A4 and 5-alpha reductase pathways [2].

The clinical question is whether competitive inhibition at CYP3A4 between these two substrates raises vardenafil plasma levels to a clinically meaningful degree. The answer, based on available pharmacokinetic data, is likely no. Progesterone at standard HRT doses (100 to 200 mg nightly) does not behave as a CYP3A4 inhibitor in the way that ketoconazole or ritonavir does. A 2003 study in the Journal of Clinical Pharmacology demonstrated that progesterone at therapeutic concentrations showed negligible inhibitory potency against CYP3A4 substrates in human liver microsomes [3]. Vardenafil's Cmax increases meaningfully only with potent CYP3A4 inhibitors: ketoconazole 200 mg increased vardenafil AUC by 10-fold, and erythromycin raised it 4-fold [1].

Standard progesterone HRT doses produce no comparable inhibition. The FDA label for vardenafil does not list progesterone among drugs requiring dose reduction.

Pharmacodynamic Interaction: The Sedation and Hypotension Overlap

This is where clinicians should focus attention. Oral micronized progesterone generates the neurosteroid metabolite allopregnanolone, a potent positive allosteric modulator of GABA-A receptors [4]. This metabolite produces the well-documented sedation and dizziness associated with bedtime progesterone dosing. The Prometrium label reports dizziness in 24% and somnolence in 8% of users in key trials [2].

Vardenafil, as a PDE5 inhibitor, produces vasodilation through the nitric oxide/cGMP pathway. Its label reports dizziness in 2% of users and headache in 15% [1]. Orthostatic hypotension occurs in a small percentage, particularly with concomitant alpha-blockers or antihypertensives.

The combination creates an additive risk profile for:

• Dizziness (progesterone's GABAergic effect plus vardenafil's vasodilation)
• Postural lightheadedness (especially if standing quickly after sexual activity)
• Excessive sedation (relevant for patients already on other CNS-active medications)

A 2016 review in Menopause documented that allopregnanolone concentrations peak 1 to 3 hours after oral progesterone administration, producing maximal sedation during this window [5]. If vardenafil is taken within this same window, the patient experiences peak vasodilation (Tmax 0.7 to 0.9 hours for vardenafil) overlapping with peak neurosteroid sedation.

Who Actually Takes Both Drugs Together?

This combination arises in several distinct clinical populations. The most common scenario involves transgender women on feminizing HRT who retain erectile tissue and wish to maintain erectile function for sexual activity. Progesterone is increasingly prescribed as part of feminizing regimens, though its role remains debated by the Endocrine Society [6].

A second population includes cisgender women prescribed off-label PDE5 inhibitors for female sexual arousal disorder (FSAD). A 2008 randomized trial by Caruso et al. (N=98) in the Journal of Sexual Medicine showed that sildenafil improved arousal in postmenopausal women on HRT [7]. Vardenafil has been studied similarly, though with fewer published trials in this population.

The third group comprises cisgender men whose female partners use topical progesterone creams, raising the question of transdermal exposure. This concern is largely theoretical at standard application sites and quantities.

Severity Rating Across Drug Interaction Databases

Major clinical decision-support systems do not flag vardenafil plus progesterone as a significant interaction. This stands in clear contrast to vardenafil's well-established major interactions:

• Nitrates (absolute contraindication, risk of fatal hypotension) [1]
• Potent CYP3A4 inhibitors like ketoconazole, itraconazole, ritonavir (require dose reduction to 2.5 mg with strict maximum frequency) [1]
• Alpha-blockers (require 6-hour dosing separation and hemodynamic stabilization) [1]
• QT-prolonging agents (vardenafil prolongs QTc by approximately 8 ms at 10 mg) [8]

The vardenafil-progesterone pair does not appear in any of these high-risk categories. Lexicomp classifies the interaction as "monitor therapy" at most, primarily due to the theoretical additive CNS depression. The Clinical Pharmacology database from Elsevier does not generate an interaction alert for this pair.

QTc Consideration

One area requiring careful thought involves cardiac electrophysiology. Vardenafil produces a dose-dependent QTc prolongation: 8 ms at the therapeutic 10 mg dose and 10 ms at the supratherapeutic 80 mg dose, as shown in a thorough QT study included in the FDA label [1]. This effect led the FDA to include a precaution against use in patients with congenital QT prolongation or those taking Class IA or III antiarrhythmics.

Progesterone itself does not prolong QTc. Some data suggest progesterone may actually shorten the QT interval through effects on cardiac ion channels [9]. A 2012 study in Heart Rhythm by Nakagawa et al. showed that progesterone shortened action potential duration in isolated cardiomyocytes. This means the combination carries no additive QT risk and progesterone might theoretically offset vardenafil's mild QT effect, though this has never been tested in a combined clinical trial.

Dose Adjustments and Practical Prescribing

For most patients, no dose adjustment is needed for either drug when used together. The standard recommendations remain:

Vardenafil dosing (unchanged by progesterone co-administration):

• Starting dose: 10 mg taken 60 minutes before sexual activity
• Range: 5 to 20 mg based on efficacy and tolerability
• Maximum frequency: once daily
• Staxyn (ODT formulation): 10 mg only, not interchangeable with film-coated tablets due to higher bioavailability [1]

Progesterone dosing (unchanged by vardenafil co-administration):

• Standard HRT: 200 mg orally at bedtime for 12 days per 28-day cycle (sequential) or 100 mg nightly (continuous)
• Transgender protocols: 100 to 200 mg nightly or 100 mg rectally

The one scenario requiring dose modification involves hepatic impairment (Child-Pugh B or C). Both drugs depend heavily on hepatic metabolism. Vardenafil should be started at 5 mg in moderate hepatic impairment and is not recommended in severe impairment [1]. Progesterone clearance is also reduced in liver disease [2]. Patients with hepatic dysfunction using both drugs should be monitored more closely for prolonged sedation and hypotension.

Timing Optimization Strategy

The simplest clinical intervention to minimize the pharmacodynamic overlap is temporal separation. Progesterone's peak sedation effect occurs 1 to 3 hours post-dose. Vardenafil's peak vasodilation occurs at approximately 1 hour post-dose, with a 4 to 5 hour half-life.

Practical approach: take progesterone at bedtime as directed, and dose vardenafil at least 4 hours before or after progesterone. For patients who take progesterone at 10 PM and plan sexual activity, dosing vardenafil at 6 PM (4 hours prior) means peak vasodilatory effects will have substantially diminished by the time allopregnanolone levels climb.

Alternatively, for patients on continuous nightly progesterone who find the temporal separation impractical, the combination can be taken closer together with the understanding that dizziness may be slightly more pronounced. This is a tolerability issue, not a safety red flag.

Monitoring Parameters

Clinicians should document the following at follow-up visits when patients use both medications:

• Orthostatic blood pressure (seated and standing, 1-minute interval)
• Symptom inquiry: dizziness, lightheadedness, syncope, excessive drowsiness
• Falls risk assessment (particularly in older patients)
• Medication reconciliation for additional CYP3A4 inhibitors or CNS depressants that could compound effects
• QTc assessment only if the patient has cardiac risk factors or uses other QT-prolonging drugs

No routine laboratory monitoring (hepatic panels, drug levels) is required solely because of this drug combination.

Special Populations

Transgender women: This population often uses estradiol, spironolactone, and progesterone simultaneously. Spironolactone has its own hypotensive effect, and combining it with vardenafil and progesterone creates a triple overlap for dizziness and orthostatic symptoms. The 2017 Endocrine Society Guidelines recommend monitoring blood pressure in transgender women on anti-androgen therapy [6]. Adding vardenafil to this regimen warrants explicit counseling about postural precautions.

Older adults (65+): Vardenafil's starting dose is already 5 mg in patients over 65 due to reduced clearance (AUC 52% higher than in younger men) [1]. Progesterone sedation also tends to be more pronounced in older patients. This group benefits most from the timing-separation strategy.

Patients on concomitant CYP3A4 inhibitors: If a patient takes moderate CYP3A4 inhibitors (erythromycin, fluconazole, verapamil) alongside both vardenafil and progesterone, the vardenafil dose should be reduced per label guidance (not exceeding 5 mg per 24 hours with erythromycin, for example) [1]. The progesterone does not meaningfully add to this pharmacokinetic burden, but the total inhibitor load matters.

What the Evidence Does Not Show

No published randomized controlled trial has specifically studied the vardenafil-progesterone combination. No case reports of serious adverse events from this pairing appear in the FDA Adverse Event Reporting System (FAERS) database or in PubMed literature through 2026. The absence of evidence is not evidence of absence, but given that millions of prescriptions for both drugs have been dispensed since vardenafil's FDA approval in 2003 and Prometrium's approval in 1998, a signal would likely have emerged if a clinically dangerous interaction existed.

The interaction profile here is best characterized as pharmacodynamically additive for sedation and dizziness, pharmacokinetically negligible, and clinically manageable with timing adjustments and patient education.

Patients should be told: "You may feel slightly more dizzy or drowsy than usual if you take these medications close together in time. Take your progesterone at bedtime as directed and allow at least 4 hours of separation from vardenafil when possible. Stand up slowly after resting or sexual activity. Report any fainting episodes to your prescriber."